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Psychological stress and atopic dermatitis (AD) symp-
toms appear to form a vicious cycle. This study compared 
the degree of stress and impairment of dermatology life 
quality between patients with AD and healthy controls, 
and examined for neuropeptides and neurotrophins asso-
ciated with stress in AD. Questionnaires, comprising five 
tests evaluating depression, anxiety, interaction anxious-
ness, private body consciousness, and dermatology life 
quality, were examined in age- and sex-matched patients 
with AD (n = 28) and healthy controls (n = 28). Immuno-
histochemical staining of nerve growth factor, substance 
P, corticotrophin-releasing factor receptor and neuro-
peptide Y was performed in the AD-involved and normal 
skin. Patients with AD showed high scores on all of the 
questionnaires, including Beck Depression Inventory, 
state anxiety, trait anxiety, Interaction Anxiousness Scale, 
Private Body Consciousness subscale, and Dermatology 
Life Quality Index. All of the parameters, except for Beck 
Depression Inventory, showed higher values in AD than 
healthy controls (p < 0.001). Statistically significant cor-
relations were observed between each psychological pa-
rameter and Dermatology Life Quality Index. Among the 
clinical parameters, only pruritus was positively correla-
ted with state anxiety (R = 0.573, p < 0.05) and trait anxiety 
(R = 0.525, p < 0.05). The Eczema Area and Severity Index 
score did not show any significant correlations with psy-
chological parameters. Nerve growth factor-reactive cells 
were observed more abundantly and intensely in both 
epidermis and dermis of AD involved skin (n = 4) than in 
healthy controls (n = 3) (p = 0.022 and 0.029, respectively). 
Also, the number and intensity of neuropeptide Y-positive 
cells was significantly greater in the entire epidermis of 
patients with AD than in healthy controls (n = 3) (p = 0.029 
and 0.026, respectively). We conclude that anxiety may be 
associated with the induction of pruritus through neuro-
peptide Y and nerve growth factor. Key words: stress; 
questionnaire; atopic dermatitis; neuropeptide Y; nerve 
growth factor.
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Atopic dermatitis (AD) is a chronic relapsing skin di-
sease, characterized by pruritic and eczematous skin 
lesions. AD can lead to psychological disturbances, such 
as stigmatization, social isolation, and discrimination (1). 
Both children and adults with AD have been reported to 
exhibit anxiety, depression, and emotional excitability 
(2, 3). Psychological interventions and programmes are 
reported to be more effective than conventional treat-
ments alone, in terms of severity of eczema, subjective 
severity, and effect on quality of life (4). 
Psychological stress and AD symptoms seem to 
form a vicious cycle (5). However, it remains unclear 
how stress affects AD. Evidence suggests that stress 
stimulates the hypothalamic-pituitary-adrenal (HPA) 
axis to induce shifting toward a T helper type 2 (Th2) 
cell pheno type, releases neuropeptide and neurotrophin, 
which influence the development and course of AD, 
induces epidermal barrier dysfunction, and lowers the 
itch threshold (6). Among the neuropeptides and neuro-
trophins, substance P (SP) and nerve growth factor 
(NGF) may be useful markers of disease activity in 
patients with AD (7). Neuropeptide Y (NPY) is released 
from sympathetic nerve endings, together with norad-
renalin, and enhances synergistically adrenergic action 
(8). Vascular instability that is observed in patients with 
AD, such as white dermographism, lower basic tempe-
rature of acral parts of the body, and a strong tendency 
to vasoconstriction after exposure to cold temperature, 
may be partially caused by NPY (9). 
In our study, we compared the degree of stress and 
impairment of dermatology life quality between patients 
with AD and healthy individuals without a history of AD 
using questionnaires. In addition, to evaluate the rela-
tionship between stress and neuropeptide/neurotrophin 
in the development of AD skin lesions, we analysed the 
expression of various neuropeptides and neurotrophin 
in the skin through immunohistochemical staining. 
MATERIALS AND METHODS
Subjects
Thirty-four patients (20 males, 14 females; mean age 24.1 years, 
range 13–41 years), with a confirmed diagnosis of AD according 
to the criteria of Hanifin & Rajka (10), and 32 healthy controls 
(HCs) (18 males, 14 females; mean age 25.2 years, range 12–43 
years) with no history of atopic diseases, were enrolled in this 
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study. None of the subjects had any other concomitant dermato-
logical disorders or medical disorders including psychological 
disorders. This study was approved by the institutional review 
board and informed consent was obtained from each patient, 
and from parents in the cases of paediatric patients, before they 
participated in the study. 
Questionnaires
The questionnaires consisted of five tests, four of which eva-
luated psychological stress; depression, anxiety, interaction 
anxiousness, private body consciousness, and one for assessing 
quality of life. 
Assessment of degree of stress in the subjects
The Beck Depression Inventory (BDI) is a 21-item test pre-
sented in multiple choice format that measures the presence 
and degree of depression in adolescents and adults (11). The 
Korean version of the BDI demonstrated good psychometric 
properties (12). Each item is evaluated using scores 0–3. The 
severity increases with the score. 
The Spielberger State-Trait Anxiety Index (STAI) comprises 40 
questions; 20 regarding state anxiety (SA) and 20 regarding trait 
anxiety (TA) (13). SA refers to the level of anxiety felt when the 
person completes the questionnaires. Trait anxiety refers to the 
anxiety felt in general by that person. The Korean version of the 
STAI was previously shown to exhibit excellent psychometric 
properties (14). Each question is evaluated using scores 1–4. 
Interaction Anxiousness Scale (IAS) was constructed to 
measure the tendency to feel nervous in social encounters 
independent of patterns of inhibited, reticent, or avoidant 
behaviour (15). It consists of 15 items that span a broad range 
of anxiety-evoking situations, including interactions with 
strangers, parties, dealings with authority figures, cross-sexed 
encounters, and casual conversation. Each item is evaluated 
using scores 0–4. 
Private body consciousness (PBC) subscale is one of three 
subscales of the body consciousness questionnaire (16). Its 
five questions assess attention to internal physical sensations, 
such as dry mouth, hunger, and body temperature. Questions 
are rated on a 6-point scale, with 0 representing an “extremely 
uncharacteristic” quality, and 5 representing an “extremely 
characteristic” quality. 
Assessment of dermatology quality of life in the subjects
The Dermatology Life Quality Index (DLQI) is a 10-question, 
self-administered questionnaire rating the life quality of daily 
functioning on a four-point scale from 0 to 3 (17). Patients are 
asked to recall, for the past week, symptoms and feelings, daily 
activities, leisure, work and school, personal relationships, and 
treatment. 
Assessment of clinical severity
Clinical severity was quantified using the Eczema Area and 
Severity Index (EASI). Two horizontal visual analogue scales 
(VASs) were used to assess patients with regards to subjective 
measures of pruritus and loss of sleep (LOS), with the anchors 
of no pruritus/no LOS at 0 and most severe at 10.
Immunohistochemistry
Formalin-fixed, paraffin-embedded skin sections were depa-
raffinized with xylene and graded ethanol. After washing with 
phosphate-buffered saline (PBS), sections were incubated in 
normal goat serum. Sections were then incubated at 4ºC over-
night with polyclonal rabbit antibodies against NPY (Chemicon, 
Billerica, MA, USA), polyclonal rabbit antibodies against NGF 
(Abcam plc., Cambridge, UK), polyclonal guinea pig antibo-
dies against SP (Abcam plc., Cambridge, UK), and polyclonal 
goat antibodies against corticotrophin releasing factor (CRF) 
receptor 1 (Santa Cruz Biotechnology Inc., CA, USA). The 
sections were washed with PBS and then incubated with bioti-
nylated goat anti-rabbit IgG antibody. Slides were washed with 
PBS and then incubated with an avidin–biotinylated peroxi-
dase complex. Peroxidase activity was visualized using stable 
diaminobenzidine. Staining was monitored under a brightfield 
microscope, and sections were washed with distilled water to 
stop the reaction. Sections were then counterstained with methyl 
green, washed, and mounted. 
In the epidermis and dermis, NGF and NPY reactive cells were 
semi-quantitatively estimated using two scores; intensity score 
from 0 to 3 (0 = no staining, 1 = weak, 2 = moderate, 3 = high) 
and positive score from 0 to 3 (0 = no staining, 1 = positive cells 
< 25%, 2 = positive cells 25–50%, 3 = positive cells > 50%). 
Data analysis
Statistical analyses were performed using the Statistical 
Product and Service Solutions program (SPSS Inc., Chicago, 
Ill, USA) for Windows (version 12). Results are reported as 
mean ± standard deviation (SD). Mann-Whitney U test was used 
to determine the statistical significance of differences in degree 
of stress and dermatology life quality between patients with AD 
and control subjects. The correlation between degree of stress 
and DLQI and clinical conditions were analysed via Pearson’s 
correlation test. Mann-Whitney U test was used to determine the 
statistical significance of differences of expression level of NGF 










Age (years), mean ± SD (range) 24.8 ± 8.1 (13–41) 26.1 ± 9.3 (13–46) 24.6 ± 7.8 (13–41) 24.8 ± 8.0 (13–41)
Gender, n
Male 21 20 18 18
Female 13 12 10 10
EASI score, mean ± SD (range) 21.9 ± 12.7 (5.6–58) 23 ± 13.3 (5.6–58)
Pruritus (0–10), mean ± SD (range) 6.8 ± 1.7 (4–10) 7.1 ± 1.5 (5–10)
Loss of sleep (0–10), mean ± SD (range) 5.7 ± 2.9 (0–10) 5.3 ± 3.2 (0–10)
Peripheral blood eosinophil count (number/μl), mean ± SD 436.5 ± 315.2 405.8 ± 335.1
Total serum IgE level (IU/ml), mean ± SD 2450.8 ± 1800.6 2461.1 ± 1930.6
AD: atopic dermatitis; EASI: Eczema Area and Severity Index; IgE: immunoglobulin E.
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and NPY through immunohistochemistry. A difference with a 
p-value < 0.05 was considered statistically significant.
RESULTS
For the 34 patients with AD, the mean EASI score 
was 21.9 ± 12.7 (5.6–58) and the mean pruritus and 
LOS scores were 6.8 ± 1.7 (4–10) and 5.7 ± 2.9 (0–10). 
Peripheral blood eosinophil count was 436.5 ± 315.2/µl 
and total serum IgE level was 2450.8 ± 1800.6 IU/ml. 
In excluding the effect of age and sex on the scales of 
stress and quality of life, we selected 28 patients with 
AD and 28 normal subjects among 66 participants after 
matching these variables. After matching age and sex, 
the mean EASI score was 23.3 ± 13.3 (5.6–58) and the 
mean pruritus and LOS scores were 7.1 ± 1.5 (5–10) 
and 5.3 ± 3.2 (0–10), respectively. Peripheral blood 
eosinophil count was 405.8 ± 335.1/µl and total serum 
IgE level was 2461.1 ± 1930.6 IU/ml (Table I).
Analysis of psychological parameters, quality of life 
and atopic dermatitis symptoms
As shown in Fig. 1, patients with AD showed high 
scores on all of the questionnaires including BDI, SA, 
TA, IAS, PBC subscale, and DLQI. And all of the pa-
rameters except for BDI showed higher values in AD 
compared with HCs (p < 0.001). Statistically significant 
positive correlations were observed between each 
psychological parameter (BDI, SA, TA, IAS, and PBS 
subscale) and DLQI. In particular, the PBC subscale 
showed the most significantly positive correlation with 
DLQI (R = 0.662, p < 0.01). IAS showed significantly 
positive correlations with both SA (R = 0.714, p < 0.01) 
and TA (R = 0.785, p < 0.01). 
Among clinical parameters, only pruritus was posi-
tively correlated with SA (R = 0.573, p < 0.05) and TA 
(R = 0.525, p < 0.05) (Fig. 2). The EASI score did not 
show any significant correlations with psychological 
parameters. Furthermore, even when patients with AD 
were classified into three groups (< 15, 15–30, > 30) ac-
cording to the EASI scores, the values of the BDI, SA, 
TA, IAS, and PBC subscale were not correlated with 
the severity of AD. LOS, peripheral blood eosinophil 
count, and total serum IgE level were not correlated 
with the psychological parameters and DLQI. 
Analysis of immunohistochemistry
The expression of substance P and CRF receptor bet-
ween AD and HC skins was not significantly different. 
NGF-reactive cells were observed more abundantly 
and more densely in both the epidermis and dermis 
of the AD-involved skins (n = 4) than in HCs (n = 3) 
(p = 0.022 and 0.029, respectively) (Fig. 3a, b; Table 
II). In the epidermis, strong immune reactive cells were 
observed in the basal layers. Most of the NGF-reactive 
cells in the dermis were small and rounded, and some 
were spindle-like or dendritic in appearance. Also, the 
number of NPY-positive cells and intensity of NPY 
were significantly greater in the entire epidermis of AD-
involved skins than in HCs (n = 3) (p = 0.029 and 0.026, 
respectively) (Fig. 4a, b; Table III). However, NPY was 
not stained in the dermis of either AD-involved and 
HCs skins. The difference in intensity and positivity 
between both AD-involved and HCs skins was slightly 
larger for NPY staining than for NGF staining, but 
without statistical significance. 
Fig. 1. Comparison of Beck Depression Inventory (BDI), Spielberger State-
Trait Anxiety Index (STAI), Interaction Anxiousness Scale (IAS), Private 
Body Consciousness (PBC) subscale, and Dermatology Life Quality Index 
(DLQI) between atopic dermatitis group and control group. Except for BDI, 
all of the parameters showed higher scores in patients with atopic dermatitis 
than in normal individuals (p < 0.001).
Fig. 2. Correlations between degree of 
pruritus and state–trait anxiety index in 
patients with atopic dermatitis. 
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DISCUSSION
It is important to measure the degree of various psy-
chological parameters in patients with AD in order 
to investigate the role of psychological stress in AD. 
Psychological stress can include many components, 
such as depression, social interaction and anxiety. In 
our study, we tried to determine psychological indices 
that were closely associated with symptoms of AD. 
It is widely accepted that anxiety and depression are 
important components. These components have been 
dealt with in many articles about psychological stress 
in AD. Additionally, we took IAS and PBC subscales 
into account in our questionnaires. 
In our study, a diagnosis of AD was performed 
through Hanifin and Rajka’s criteria. Minor diagnostic 
features of the criteria, which may be less frequent in a 
community setting where mild or moderate cases pre-
dominate, cause their lack of simplicity and validation. 
Although not suitable for community studies, the criteria 
would be better in hospital-based settings, in our study 
also, due to their high sensitivity.
Regarding the unfavourable appearance of AD lesions, 
adult patients with AD usually felt anxiety, especially in 
social activities relating to other people. Since STAI can 
assess only present and general anxiety, it was needed 
to assess anxiety in interacting with other people; the 
IAS scale was used. Additionally, many patients with 
AD seemed to have features of hypochondriasis. They 
not only worry about their AD, but also other nume-
rous physical problems, such as adverse effects of the 
long-term application of topical steroids. We therefore 
used the PBC subscale to assess patients with AD and 
hypochondriatic features. 
In our study, both scores of IAS and PBC subscale 
were higher in AD compared with HCs, and were 
positively correlated with DLQI (R = 0.660, p < 0.01; 
R = 0.662, p < 0.01, respectively). High IAS scores 
mean social avoidance and inactivity in personal rela-
tionships. Unfavourable appearance, such as red face 
and severe lichenification caused by AD, might account 
for this. In addition, high scores on the PBS subscale in 
patients with AD might originate from the chronicity 
and intractable features of AD, which can make patients 
with AD worry about their body and become very sen-
sitive to their internal physical sensation. Therefore, 
these two stress profiles were closely correlated with 
dermatological quality of life, and might be considered 
to be important profiles that reflect the quality of life in 
patients with AD.
Arima et al. (18) reported that depression was obser-
ved more commonly in patients with AD than in healthy 
individuals. In our study, the BDI score, which displays 
the status of depression, was slightly higher in AD 
than in healthy individuals, and there was no statistical 
significance between AD and HCs. When it comes to 
anxiety in AD, most studies found that both children and 
adults with AD have a higher anxiety level than controls 
(19–21). Hashizume et al. (22) reported that both TA 
and SA are significantly higher in adult patients with AD 
than in controls, and the score of TA was significantly 
higher than that of SA in their AD patient group. Our 
study also demonstrated that both scores of TA and SA 
were significantly higher in patients with AD and the 
score of TA was significantly higher than that of SA 
(p = 0.004, 55.1 ± 14.1 vs. 50.5 ± 12.6). 
In our data, TA and SA were not correlated with 
EASI score. It is still controversial whether anxiety 
Fig. 3. Immunohistochemical 
staining of nerve growth factor 
in atopic dermatitis-involved 
skin (A; original magnification 
×200) and normal skin (B; original 
magnification ×200). NGF immuno-
reactive cells were observed to 
be more numerous and dense in 
the epidermis and dermis of AD-
involved skin than in controls. Basal 
layers of epidermis showed strong 
reaction to NGF. 
Table II. Examination of nerve growth factor (NGF) expression in atopic dermatitis and normal skins through immunohistochemical staining
Epidermis Dermis
Intensity score NGF-positive score Intensity score NGF-positive score
Healthy control (n = 3), mean (SD) 1 ± 0 1 ± 0 0.67 ± 0.58 0.67 ± 0.58
Atopic dermatitis (n = 4), mean (SD) 2.75 ± 0.5 2.75 ± 0.5 2.5 ± 0.58 2.5 ± 0.58
p-value 0.022 0.029
Intensity score: no staining (0), weak (1), moderate (2), high (3). 
NGF-positive score: no staining (0), positive cells < 25% (1), 25–50% (2), > 50% (3).
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levels are correlated with the severity of AD (23). Since 
various immune and non-immune factors participate in 
the pathogenesis of AD, anxiety cannot be attributed 
solely to increased disease activity. However, TA and 
SA were positively correlated with pruritus. It has long 
been recognized that stress triggers or enhances pruritus 
through lowering the itching threshold (24, 25). The 
mechanism of how stress lowers the itch threshold is 
not clear. However, neuropeptides and neurotrophins are 
recognized as a crucial mediator associated with the me-
chanism of itching (26–28). Therefore, we investigated 
the expression of neuropeptides and neurotrophins in 
atopic skin that have been known to be associated with 
itching and anxiety. Although substance P is regarded as 
a useful marker of disease activity in AD, the difference 
in the expression of substance P between AD and HC 
skins was not remarkable in our study. We investigated 
the expression of NGF and NPY, which have been re-
ported to be strongly associated with anxiety. 
Besides function as a trophic factor of neuropeptider-
gic and sympathetic neurons, NGF is now increasingly 
regarded as a potent immunomodulator, promoting inter-
actions between neuronal and immune cells (27). It has 
been reported that the most likely psychological substrate 
in anxiogenic stimuli could be NGF (29–32). Research 
investigating NGF in soldiers experiencing parachute 
jumping for the first time suggested that anticipatory 
anxiety might be responsible for NGF release (33). Ad-
ditionally, NGF is particularly considered as one of the 
most important mediators lowering the itching threshold. 
Recently, Peter et al. (34) reported the relationships bet-
ween stress and peptidergic innervation and mast cell 
degranulation in murine skin. Increased contact between 
nerve fibre and mast cells induced by stress may account 
for a lowered itching threshold. Our findings that the 
epidermis of AD lesions showed a higher expression of 
NGF compared with HCs were consistent with previous 
studies (35). Given the findings that the presence of 
intraepidermal mast cells is a characteristic of AD (36, 
37), NGF expression in the epidermis of AD lesions is 
expected to induce activation of mast cells and exacerbate 
itching. In addition, it has been reported that fibroblasts 
and inflammatory cells, such as mast cells, lymphocytes, 
and eosinophils, can release NGF (38–40). In our study, 
inflammatory cells and fibroblasts in the dermis of AD 
lesions showed a higher expression of NGF. 
NPY have been reported to have an anxiolytic effect 
via Y1 receptor in mice brains (41). Mutant mice lacking 
NPY show increased anxiety-like behaviour on various 
tests (42). In addition, low levels of NPY in plasma and 
cerebrospinal fluid have been found in patients with 
anxiety disorders (43). Altogether, it is considered that 
secretion of NPY has a protective role toward anxiety. 
Additionally, NPY in the central nervous system plays 
multiple roles in increasing food intake and decreasing 
physical activity (44). However, the reports regarding the 
role of NPY in AD have been limited. One report showed 
that AD skin lesions appeared in higher expressions of 
NPY (45). Another study demonstrated that the level of 
NPY in the plasma of patients with AD was elevated 
during exacerbation of the disease and further increased 
during remission (9). It was assumed that a lower plasma 
level of NPY during exacerbation rather than during 
remission originated from a selective uptake of NPY in 
the lesional skin. In our study, NPY-staining cells were 
observed more abundantly in the entire epidermis of AD 
lesions than in normal skins and NPY-staining was quite 
sparse in the dermis. In vitro, NPY have been reported to 
activate mast cell and stimulate angiogenesis (46, 47). 
The present cross-sectional study has limitations in 
confirming whether anxiety is premorbid to pruritus 
with sufficient aetiological significance. However, as 
mentioned above, stress including anxiety has been 
reported to trigger and enhance pruritus. Furthermore, 
Fig. 4.  Immunohistochemical 
staining of neuropeptide Y (NPY) 
in atopic dermatitis (AD)-involved 
skin (A; original magnification 
×200) and normal skin (B; original 
magnification ×200). NPY immuno-
reactive cells were observed to be 
more numerous and dense in the 
entire epidermis of AD-involved skin 
than in control skin. NPY immune 
reactivity was not observed in the 
dermis of either AD-involved or 
control skin.
Table III. Examination of neuropeptide Y (NPY) expression in 
atopic dermatitis and normal skin through immunohistochemical 
staining
Epidermis
Intensity score NPY-positive score
Healthy control (n = 3) 0.67 ± 0.58 0.67 ± 0.58
Atopic dermatitis (n = 4) 2.25 ± 0.5 2.5 ± 0.58
p-value 0.026 0.029
Intensity score: no staining (0), weak (1), moderate (2), high (3)
NPY-positive score: no staining (0), positive cells < 25% (1), 25–50% (2), 
> 50% (3).
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neuro-immune mediators, including NGF and NPY 
induced by anxiety, have been reported to be associated 
with pruritus. In our study, patients with AD who had 
high scores of SA, TA, and pruritus showed more intense 
NPY/NGF reactivity in the skin, although these were 
not statistically confirmed due to the limited numbers 
of specimens and there might be variation according 
to the severity of obtained skin lesions (Fig. 5a–d). 
These results suggested that anxiety may upregulate 
the expression of NGF and release NPY, both of which 
could contribute to pruritus. Thus, our study suggested 
that anxiety might be associated with the induction of 
pruritus through NGF and NPY. In addition, our results 
supported the necessity of management to reduce an-
xiety, such as relaxation therapy, educational program-
mes, and anxiolytics.
Besides BDI and STAI, which have been evaluated 
frequently in various psychosomatic studies, new scales 
such as IAS and PBC subscale, were also confirmed to 
be higher in patients with AD compared with healthy 
individuals. In addition, as anxiety among psychological 
profiles was closely correlated with pruritus, psycho-
logical approaches that can reduce anxiety might be con-
sidered in cases of patients with AD who do not respond 
to anti-histamines in the management of pruritus of AD. 
However, further studies that can support the relevance 
of psychological aspects in the pathogenesis of AD and 
the association between anxiety and pruritus are required. 
Moreover, as the effects of psychological management 
have been estimated only through severity of eczema and/
or psychological parameters until now, studies to discover 
key molecules linking stress and severity of AD symp-
toms are necessary. In conclusion, dermatologists should 
understand the psychological characteristics of patients 
with AD and be aware of necessary treatment methods 
to help patients regulate stress conditions according to 
individual psychological characteristics. 
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